Business
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company.
About this update from Q32 Bio Inc.
[{"type":"text","content":"-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience --","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company.","length":430,"tagName":"p"},{"type":"text","content":""Adrien has a proven track record of success in roles that span clinical development and medical affairs supporting commercial launches. She brings deep I&I expertise that will be invaluable as we advance bempikibart in the ongoing Part B and open-label extension portions of the SIGNAL-AA Phase 2a clinical trial in patients with alopecia areata. We are thrilled to welcome Adrien to the team," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We would also like to thank Jason for his contributions to Q32 Bio and for his role advancing bempikibart into Phase 2 clinical development."","length":619,"tagName":"p","attribs":{}},{"type":"text","content":""It's an exciting time to join Q32 Bio as we advance the SIGNAL-AA Phase 2a clinical trial and approach topline results from the Part B portion in the first half of next year. Bempikibart, a fully human anti-IL-7Rα antibody that blocks IL-7 and TSLP signaling, is a novel approach to treating alopecia areata and clinical data to date show promising potential for patients in need of new treatment options," said Dr. Sipos. "I look forward to helping Q32 Bio advance bempikibart and have a meaningful impact for patients living with alopecia areata and other autoimmune and inflammatory diseases."","length":621,"tagName":"p","attribs":{}},{"type":"text","content":"Prior to joining Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc., where she advised both large and emerging biopharmaceutical companies on clinical development and medical affairs initiatives across multiple therapeuti...